SNAIL1 action in tumor cells influences macrophage polarization and metastasis in breast cancer through altered GM-CSF secretion by Brenot, Audrey et al.




SNAIL1 action in tumor cells influences
macrophage polarization and metastasis in breast





Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Brenot et al. Oncogenesis  (2018) 7:32 
DOI 10.1038/s41389-018-0042-x Oncogenesis
ART ICLE Open Ac ce s s
SNAIL1 action in tumor cells inﬂuences
macrophage polarization and metastasis in
breast cancer through altered GM-CSF
secretion
Audrey Brenot1,2, Brett L. Knolhoff1,2, David G. DeNardo1,2 and Gregory D. Longmore1,2,3
Abstract
The EMT inducer SNAIL1 regulates breast cancer metastasis and its expression in human primary breast tumor predicts
for poor outcomes. During tumor progression SNAIL1 has multiple effects in tumor cells that can impact metastasis.
An inﬂammatory tumor microenvironment also impacts metastasis and recently SNAIL1 has been implicated as
modulating the secretion of cytokines that can inﬂuence the tumor immune inﬁltrate. Using a spontaneous genetic
model of breast cancer metastasis and syngeneic orthotopic transplant experiments we show that the action of
SNAIL1 in primary breast tumor cells is required for breast tumor growth and metastasis. It does so, in part, by
regulating production of GM-CSF, IL1α, IL-6, and TNFα by breast cancer cells. The SNAIL1-dependent tumor cell
secretome modulates the primary tumor-associated macrophage (TAM) polarization. GM-CSF alone modulates TAM
polarization and impacts breast cancer metastasis in vivo. This study highlights another role for breast tumor SNAIL1 in
cancer progression to metastasis—modulation of the immune microenvironment of primary breast tumors.
Introduction
Breast cancer is the most prevalent cancer among
women. Despite signiﬁcant advances in diagnostic mod-
alities and treatments, metastatic spread of breast cancer
still results in high mortality rate. Cancer metastasis is a
multistep process characterized by local invasion, intra-
vasation, transit through the circulation, extravasation,
and survival and proliferation at distant sites. Due to this
multistep nature of cancer metastasis there are many cell
biological processes that can vary depending upon ana-
tomic localization. One such process, epithelial to
mesenchymal transition (EMT), has been implicated as
contributing to metastasis at the primary site, during
hematogenous spread, and at the metastatic site1,2.
Importantly EMT exhibits a great deal of plasticity, or
reversibility, particularly at the different anatomic loca-
tions, or environments, during cancer progression to
metastasis. At the primary tumor site, activation of this
program in tumor cells is thought to contribute to tumor
cell invasion and migration, allowing tumor cells to exit
the primary tissue to metastasize3.
Several transcription factors act as EMT inducers dur-
ing normal development and cancer progression to
metastasis. SNAIL1, in particular, is a major regulator of
early developmental EMT (gastrulation) and genetic
deletion of SNAIL1 in breast tumor cells dramatically
inhibits metastasis in mouse models of breast cancer4,5.
The action of SNAIL1 has been implicated in multiple
cellular processes including, cell proliferation and survi-
val, cell invasion and migration, and tumor initiating
potential6. Within breast tumors SNAIL1 is expressed in
mammary carcinoma cells as they progress to invasive-
ness, as well as in cells within the tumor stroma7. SNAIL1
protein expression in carcinomas seems to be particularly
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enhanced in cells at the tumor-stromal interface7. In
human breast tumors SNAIL1 expression in primary
breast cancer cells is associated with higher recurrence,
more aggressive tumors, and poorer outcomes8.
An inﬂammatory microenvironment is a well-
recognized hallmark of cancer progression9. Macro-
phages, in particular, are observed at the invasive front of
the primary breast tumors10. Macrophages display phe-
notypic and functional plasticity, and as such can be
divided into two major subsets: classical activation (M1-
like) and alternative activation (M2-like)11. Although
classicaly activated tumor-associated macrophages
(TAM) can restrain cancer development, alternatively
activated TAM often play a protumorigenic role in that
they can promote tumor cell migration and metastasis by
inﬂuencing immunosuppression, angiogenesis, and ECM
deposition and remodeling10–12. Indeed, inﬁltration or
enrichment of tumors with TAMs is associated with a
poor prognosis in many human tumors13.
Whether SNAIL1 can inﬂuence the inﬂammatory
microenvironment of tumors to further facilitate metas-
tasis, and if so how, has been addressed in a number of
models. SNAIL1 has been shown to regulate inﬂamma-
tory cytokines and chemokines in several different cell
types (macrophages, keratinocytes, melanoma cells, and
head and neck cancer cells)14–19. In some instances these
cytokines have been shown to modulate the immune
inﬁltrates within tumors and tumor size and/or metas-
tasis16–18. However, most of these studies used tumor
cells that constitutively overexpressed SNAIL1, using
vectors that would preclude transcriptional regulation of
SNAIL1 in these cells and is a situation that likely does
not occur de novo during tumor development and pro-
gression. In fact SNAIL1 levels change within tumor cells
during tumor progression, and persistent expression of
SNAIL1 actually can inhibit metastasis4. In addition, all
in vivo studies were orthotopic transplants of genetically
manipulated tumor cell lines which could induce a dif-
ferent immune inﬁltrate than spontaneous tumor models.
Finally, in addition to inﬂammatory genes, SNAIL1 reg-
ulates expression of genes known to regulate tumor cell
migration, adhesion, proliferation, and survival which are
all involved in tumor growth and metastasis. Therefore to
demonstrate a speciﬁc role of SNAIL1 regulated immune
inﬁltrate in tumor metastasis, one needs to evaluate
cytokines independent of the other SNAIL1 regulated
factors that impact metastases.
In this study we show, in both a spontaneous breast
cancer model in which the Snail1 gene was genetically
deleted in tumor cells and an orthotopic syngeneic
transplant model comparing SNAIL1-containing with
SNAIL1-depleted tumor cells that the presence of
SNAIL1 in breast tumor cells regulates secretion of
inﬂammatory mediators that inﬂuence the polarization of
the TAMs to a tumor promoting phenotype. We then
show that select modulation of GM-CSF alone, an
inﬂammatory mediator whose production by tumor cells
is controlled by SNAIL1, plays a signiﬁcant role in TAM
polarization at the primary tumor site and cancer pro-
gression to metastasis. These results indicate that
SNAIL1-mediated production of GM-CSF by tumor cells
is another important pathway whereby SNAIL1 regulates
breast cancer metastasis.
Results
Deletion of SNAIL1 in the breast epithelium reduces breast
cancer progression and metastasis to the lung
To dissect the role of SNAIL1 in breast cancer devel-
opment, progression, and metastasis, we analyzed its role
in a spontaneous genetic model of breast cancer metas-
tasis. The Snail1 gene was deleted in luminal epithelial
cells of breast tumors by generating MMTV-Cre, Snail1ﬂ/
ﬂ, MMTV-PyMT mice (SNAIL1 KO, PyMT). Breast
tumors that developed in SNAIL1 KO mice exhibited
reduced growth, as shown by a decreased tumor burden at
13 weeks (Fig S1A). This delay in tumor formation has
been recently observed5 and attributed to a reduction in
repression of wild type p53, in the absence of SNAIL1,
resulting in decreased expansion and activity of the tumor
initiating cells. Grossly, SNAIL1 KO tumors appeared
round, well demarcated from the surrounding tissues, and
less ﬂattened and invasive than WT tumors (Fig S1B,
example Fig S1C). Histologic comparison of WT, PyMT,
and SNAIL1 KO, PyMT tumors revealed signiﬁcantly less
advanced tumors in the SNAIL1 KO, PyMT mice (Fig
S1D with representatives images in Fig S1E). As pre-
viously shown5, the reduced tumor growth was not due to
impaired development of the mammary gland, as the
mammary epithelium in 4 week and 5 week old MMTV-
Cre, Snail1ﬂ/ﬂ females (SNAIL1 KO) was not different
than the epithelium of age-matched wild type females
(WT) (Fig S1F with an example shown in Fig S1G) as
assessed by whole mount staining. Deletion of SNAIL1
also led to reduction of SLUG/SNAIL2 expression indi-
cating that SNAIL1 directly or indirectly regulates levels
of SLUG (Fig S2A).
To assess the role of SNAIL1 in metastasis (independent
of its role in primary tumor growth), mice with equivalent
primary tumor burden (biggest tumor between 10 and
15mm) were assessed for lung metastasis. Compared to
WT size-matched mice (Fig. 1a), SNAIL1 KO, PyMT mice
showed signiﬁcantly reduced number of lung metastasis
(Fig. 1b). To test if this ﬁnding was restricted to the
MMTV-PyMT spontaneous model, the role of SNAIL1 in
a syngeneic orthotopic transplant model was assessed.
Equal numbers of mouse metastatic 4T1 cells; either
shScr control or SNAIL1-depleted (shSnail1) (Fig S2B)
were implanted in the mammary fat pad of syngeneic WT
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Balb/C female mice. In contrast to the spontaneous tumor
model, there was no difference in the primary tumor
burden between the two groups of mice (Fig. 1c). This
could reﬂect the fact that SNAIL1 is a suppressor of wild
type p53, not mutant p535 and 4T1 cells are p53 null20.
Despite the absence of difference in primary tumor size,
mice implanted with Snail1-depleted cells had sig-
niﬁcantly less lung metastases (Fig. 1d, e). Although the
number of lung metastases were reduced when Snail1 was
either depleted in syngeneic orthotopic transplant or
deleted in spontaneous tumor model, respectively, the size
of individual metastases was not different between WT
and shSnail1 or SNAIL1 KO mice (Fig S2C and Fig S2D,
respectively).
In sum, these data indicated that SNAIL1 played a cri-
tical role in the growth of the primary tumor in the
context of wild type p53, but also that tumor cell SNAIL1
inﬂuenced breast cancer metastasis in both a spontaneous
Fig. 1 SNAIL1 is required for breast cancer metastasis. a Total tumor burden of MMTV-PyMT, Snail1ﬂ/ﬂ (WT, PyMT) and MMTV-PyMT, MMTV-Cre,
Snail1ﬂ/ﬂ (SNAIL1 KO, PyMT) mice, determined by the sum of the volume of all tumors for each mouse at time of collection (when the largest tumor is
10–15 mm in diameter). Seven to eight mice per group. b Quantiﬁcation of lung metastasis when the largest primary tumor (as represented in Fig.
1a) is 10–15 mm. The average number is calculated by counting microscopically visible metastases on each lobe of H&E stained 5 μm sections. Seven
to eight mice per group. Tumor volume (c) and average number of lung metastasis (d) of 4T1-shScr (shScr) and 4T1-shSnail1 (shSnail1) mammary
xenografts 21 days after transplants. 10 mice per group. e Representative images of H&E stained lung sections from mice transplanted with 4T1-shScr
(shScr) and 4T1-shSnail1 (shSnail1). Scale bar, 400 μm. Data are presented as mean ± SD. *p < 0.05
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MMTV-PyMT p53 wild type genetic model and a p53
null syngeneic orthotopic transplant model, suggesting a
p53-independent role of Snail1 in metastastic progression.
Tumor cell SNAIL1 modulates TAM polarization in primary
tumors
Inﬂammation within tumors can dramatically impact
tumor progression both positively and negatively. SNAIL1
is a transcriptional regulator that directly and indirectly
affects the transcription of many genes, including
inﬂammatory modulators15,17,18. Therefore, we asked
whether the action of tumor cell-intrinsic SNAIL1 affec-
ted tumor growth and metastasis by changing the
inﬂammatory tumor microenvironment. We character-
ized the immune inﬁltrates present in SNAIL1 expressing
and SNAIL1 deleted (SNAIL1 KO or shSnail1) primary
tumors, in the spontaneous MMTV-PyMT and syngeneic
orthotopic transplant model.
Immune cells important for the establishment of an
immunosuppressive tumor microenvironment include
tumor-associated macrophages (TAM), monocytic
myeloid-derived suppressor cells (Mo-MDSC) and gran-
ulocytic MDSCs (G-MDSC). These leukocytes regulate
the adaptive lymphocytic response to tumors, and as such,
can inﬂuence tumor growth and metastasis21,22. In the
spontaneous tumor model, most myeloid cell populations
(CD45+ CD11b+ Ly6G+ Ly6C+ MHCIIlow/G-MDSC,
CD45+ CD11b+ Ly6G+ Ly6C− MHCIIhigh/Mature
Granulocytes, CD45+ CD11b+ Ly6G− Ly6C+/Mo-MDSC
as deﬁned in23) and total number of TAMs (CD45+
CD11b+ Ly6G− Ly6C− F4/80+ MHCII+) present in pri-
mary MMTV-PyMT tumors+/− Snail1 were not sig-
niﬁcantly different (Fig. 2a). Similarly, in the syngeneic
orthotopic transplant model there were no changes in
myeloid cell numbers in shSnail1 tumors (Fig. 2b). There
was no signiﬁcant difference in total T cells (CD3+), T
helper cells (CD3+CD4+) or cytotoxic T cells
(CD3+CD8+) in SNAIL1 KO or shSnail1 primary tumors
in both models (Fig. 2c, d). There was also no signiﬁcant
change in the percent of activated CD4 T cells (Fig S2E)
or activated CD8 T cells (Fig S2F). However, a higher
percent of TAMs were polarized towards an M1-like
phenotype (CD45+ CD11b+ Ly6G− Ly6C− F4/80+
MHCII+ CD206−) in SNAIL1 KO tumors, while the
percent of M2-like macrophages (CD45+ CD11b+ Ly6G−
Ly6C− F4/80+ MHCII+ CD206+) was decreased (Fig. 3a).
In the syngeneic orthotopic transplant model the same
increase in M1-like and decrease in M2-like macrophages
was observed in the tumor inﬁltrating leukocyte popula-
tion of Snail1-depleted tumors (Fig. 3b).
Classically activated macrophages (M1-like TAM)
typically express proinﬂammatory cytokines like inducible
nitric oxide synthase 2 (NOS2) and MHC II molecules
and can restrain cancer development and metastasis.
Alternatively activated macrophages (M2-like TAM) have
a decreased expression of the above markers, increased
expression of the mannose receptor (CD206) and often
play a protumorigenic role24,25. To better characterize the
effects of depleting SNAIL1 from the tumor cells on the
TAM population in the primary tumor, we analyzed gene
expression of molecules known to be differentialy
expressed in these two subsets23,26–28. TAMs were FACS-
sorted from 4T1-shScr and 4T1-shSnail1 tumors 14 days
after transplants and gene expression compared. TAMs
from SNAIL1 depleted tumors displayed increased
expression of M1-like/anti-tumor genes like Ifna1, Il12a,
Il6, Nos2, and Ifnb1. In contrast M2-like/immunosup-
pressive genes like Mrc1, Msr1, Tgfb1, Il10, and Ccl2
displayed similar or reduced expression (Fig. 3c).
Amongst these genes, the expression of the M1-like genes
Il6 and Nos2 was signiﬁcantly increased while the
expression of the M2-like genes Ccl2 and Il10 was sig-
niﬁcantly decreased when SNAIL1 was depleted (Fig. 3d)
demonstrating that depletion of SNAIL1 in the tumors
cells led to an increase in functional M1-like or classicaly
activated macrophages.
To determine how the action of SNAIL1 in tumor cells
affected TAM polarization we asked whether the presence
or absence of SNAIL1 altered the tumor cell secretome,
and thus, regulated TAM polarization through a paracrine
mechanism. Bone marrow derived macrophages were
cultured in the presence of conditioned media from
shSnail1-depleted 4T1 cells or parental 4T1 cells. Under
these conditions there was a greater proportion of mac-
rophages polarized towards an M1-like phenotype in the
presence of conditioned media from 4T1 cells depleted of
SNAIL1 compared to their polarization in the presence of
conditioned media from SNAIL1-containing 4T1 cells
(Fig. 3e). To conﬁrm that this ﬁnding was not limited to
4T1 cells, SNAIL1 expression was depleted in a cell line
derived from MMTV-PyMT tumor cells (PMT-shScr and
PMT-shSnail1). Similar to the ﬁndings with the 4T1 cells,
conditioned media from the SNAIL1-depleted PyMT cells
induced polarization of a greater number of macrophages
towards an M1-like phenotype (Fig S3A).
SNAIL1 regulates cytokine/chemokine production in breast
cancer cells
Since conditioned media from 4T1 breast tumor cells
depleted of SNAIL1 was able to recapitulate macrophage
polarization observed in vivo in primary breast tumors
lacking Snail1, we analyzed and contrasted the cytokines
and chemokines expressed by parental 4T1 and SNAIL1-
depleted 4T1 breast tumor cells. Analysis of mRNA levels
by qRT-PCR revealed increased levels of GM-CSF, IL-1α,
IL-9, CCL4, CCL5, and TNFα and decreased levels of IL-6
and CCL2 mRNA in SNAIL1-depleted cells (Fig. 4a).
Using a multiplex ELISA, we determined the level of 31
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cytokines and chemokines. Depletion of SNAIL1 led to
signiﬁcantly increased secretion of GM-CSF (also called
CSF-2), IL1α, and, TNFα as well as signiﬁcantly decreased
secretion of IL-6 (Fig. 4b). However, by ELISA analysis,
the cytokines and chemokines IL-9, CCL2, CCL4, and
CCL5 were not secreted at signiﬁcantly different levels
(Fig. 4b). We decided to focus on GM-CSF as it is known
to regulate macrophage polarization29,30.
GM-CSF recapitulates the macrophage polarization and
metastasis of Snail1-deleted tumors
To test whether GM-CSF alone could recapitulate the
various in vitro and in vivo tumor phenotypes observed in
mice with Snail1-deleted tumors, we employed multiple
approaches.
First, a neutralizing anti-GM-CSF antibody was added
to conditioned media from shSnail1 4T1 cells and mac-
rophage polarization capacity of this GM-CSF-neutralized
conditioned media assessed with WT BMDM. Neu-
tralization of GM-CSF resulted in a macrophage polar-
ization proﬁle seen when culture supernatant from
control shScr 4T1 cells (no anti-GM-CSF) was added to
BMDM; more towards an M2-like phenotype, as shown
by an increase in CD206 mean ﬂuorescence intensity, a
marker of M2-like macrophages (Fig. 5a, representative
image Fig. 5b).
Fig. 2 Immune inﬁltrates in tumors. Immunophenotyping of tumors from MMTV-PyMT, Snail1ﬂ/ﬂ (WT, PyMT) and MMTV-PyMT, MMTV-Cre, Snail1ﬂ/ﬂ
(SNAIL1 KO, PyMT) mice (a, c) or 4T1-shScr (shScr) and 4T1-shSnail1 (shSnail1) transplanted mice (b, d). The frequency of G-MDSCs
(CD11b+Ly6G+Ly6C+MHCIILow), Granulocytes (Gran.) (CD11b+Ly6G+Ly6C-MHCIIHi), Mo-MDSC (CD11b+Ly6G-Ly6C+), TAM (CD11b+Ly6G−Ly6C−F4/
80+MHCII+) (a, b) and leukocytes (CD45+), T cells (CD3+), T helper cells (CD3+CD4+) and cytotoxic T cells (CD3+CD8+) (c and d) is depicted as the
mean percentage of parent cells (as described in more details in Material and Methods). All graphs depict mean values+/− SD, n= 10 mice per
group for orthotopic transplants and 17 to 20 tumors (7 mice each) per group for the transgenic model, in all graphs, p > 0.05 by unpaired t-test
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Fig. 3 SNAIL1 modulates macrophage polarization in vivo and in vitro. a Quantiﬁcation of tumor inﬁltrated M1-like and M2-like macrophages in
MMTV-PyMT, Snail1ﬂ/ﬂ (WT, PyMT) and MMTV-PyMT, MMTV-Cre, Snail1ﬂ/ﬂ (SNAIL1 KO, PyMT) mice when the largest primary tumor reaches 10–15 mm
expressed as a percent of total TAM. 18–20 tumors per group (seven mice each). b Quantiﬁcation of tumor inﬁltrated M1-like and M2-like
macrophages in 4T1-shScr (shScr) and 4T1-shSnail1 (shSnail1) mice 21 days post transplant expressed as a percent of total TAM. Ten tumors per
group. c, d qPCR analysis on TAMs sorted from tumors 14 days post transplant expressed as the fold change of gene expression in 4T1-shSnail1
relative to 4T1-shScr. Four mice per group. All the genes analyzed are grouped as M1-like and M2-like molecules (c) and the signiﬁcantly regulated
genes are represented in (d). e In vitro M1-like polarization of bone marrow derived macrophages (BMDM) by conditioned media from 4T1-shScr
(shScr) or 4T1-shSnail1 (shSnail1) expressed as a percent of total BMDM. Representative results of two biological replicates with three technical
replicates. Data are presented as mean ± SD. *p < 0.05
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In a second approach, mice were treated for 7 days with
recombinant GM-CSF or saline solution, then mammary
glands transplanted with 4T1-shScr tumor cells and GM-
CSF or saline solution treatment continued for the
duration of the experiment. Treatment with GM-CSF did
not affect primary tumor growth at 12 days (Fig. 5c) or
25 days (Fig. 5d). Lung metastases at 12 days were very
rare in this model and their number was not affected by
treatment with GM-CSF (Fig. 6a). But at 25 days, the
metastatic burden in the lung was signiﬁcantly reduced in
mice treated with GM-CSF (Fig. 6b). Treatment with GM-
CSF also increased the percentage of M1-like macro-
phages in primary tumors at 12 days post transplant (Fig.
6c) while it was not signiﬁcantly different at 25 days (Fig.
6d). The decrease in number of lung metastasis at 25 days
in the presence of GM-CSF (Fig. 6b) could, in part, result
from the increase in M1-like polarization at 12 days (Fig.
6c). The fact that there was no difference in macrophage
polarization in the presence of GM-CSF at 25 days (Fig.
6d) is perhaps not surprising since the tumors at that
stage are necrotic.
The number of other myeloid populations and T cell
populations were not signiﬁcantly changed at either time
points (Fig S3B-E). When cells were directly introduced
into the circulation through IV injection, depletion of
SNAIL1 resulted in a signiﬁcant reduction in lung
metastasis, but treatment with GM-CSF did not sig-
niﬁcantly reduce the number of metastasis when WT cells
were injected (Fig. 6e). This indicated that, while Snail1
was required for metastatic growth in the lungs in the tail
vein assay, the GM-CSF mediated effect of Snail1 on lung
metastasis was most likely a local effect within the pri-
mary tumor and not a systemic effect.
The extent of altered M1-like TAM polarization
observed with GM-CSF treatment in the orthotopic
model (Fig. 6c) was equivalent to that observed in mice
transplanted with shSnail1-depleted 4T1 cells (Fig. 3b),
indicating that GM-CSF was likely a major regulator of
M1-like polarization in breast tumors lacking SNAIL1.
Collectively our data suggest that GM-CSF production
in SNAIL1-depleted breast tumor cells, plays a signiﬁcant
role in inhibiting breast tumor metastasis to the lung by
inﬂuencing the polarization of inﬁltrating macrophages
within the primary tumor.
Discussion
The action of SNAIL1 in breast tumor cells has been
shown, in mouse models, to be a key regulator of
metastasis4,5,31,32. The presence of SNAIL1 in human
primary breast tumors predicts for poor clinical outcomes
with increased tumor grade, nodal metastasis, and tumor
recurrence5,8,33. SNAIL1 contributes to these phenotypes
through various tumor cell functions including tumor cell
invasion and migration34,35, tumor cell survival, and
proliferation36, the maintenance of tumor initiating
cells5,6, resistance to therapy6,37, and recurrence8. Recent
studies indicate that SNAIL1 is also involved in the reg-
ulation of the immune compartment, highlighting another
way SNAIL1 is a critical player in cancer progression and
metastasis14,15,17,18. However, the mechanism by which
SNAIL1 regulates the immune compartment remains
controversial and conclusions from these studies are
limited by constitutive overexpression of Snail1 in tumor
cells, inducing levels of SNAIL1 not present during
tumorigenesis nor is the overexpressed SNAIL1 tran-
scriptionally regulated. In fact, endogenous SNAIL1
expression during breast cancer development,
Fig. 4 SNAIL1 regulates cytokine/chemokine production in breast
cancer cells. a qPCR analysis of mRNA isolated from 4T1-shScr (blue)
and 4T1-shSnail1 cells (red) with 2 ng/ml TGFβ. Each gene was
quantiﬁed from two biological replicates with three technical
replicates each and normalized to 4T1-shScr. b Relative levels of
cytokines and chemokines in conditioned media from 4T1-shSnail1
cells (red) compared to 4T1-shScr cells (blue). Cells were grown with
2 ng/ml TGFβ and protein levels were quantiﬁed in ﬁltered
supernatants by Multiplex ELISA. Each protein was quantiﬁed from
three biological replicates and normalized to the protein levels in 4T1-
shScr. Data are presented as mean ± SD. *p < 0.05
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progression, and metastasis ﬂuctuates and these changes
are critical for efﬁcient metastasis4. In the current study,
we show a direct in vivo link between SNAIL1 expression
in tumor cells and modulation of the immune inﬁltrate
within the primary tumor through GM-CSF secretion that
subsequently impacts metastasis to distant sites.
A recent study showed that tumors derived from car-
cinoma cells expressing low levels of SNAIL1 (Snaillo)
elicited a strong CD8+ T cells and M1 macrophage
response while tumors derived from carcinoma cells
expressing higher levels of SNAIL1 (Snailhi) induced a
strong regulatory T cell and M2 macrophage response38.
The association of lower levels of SNAIL1 with an M1-like
response is consistent with our ﬁndings. This study did
not elucidate the molecular mechanism by which SNAIL1
induced immunosuppression occurs, however.
SNAIL1 has been shown to regulate cytokine and che-
mokine production in several different cells (macro-
phages, keratinocytes, melanoma cells), although again
most of these studies utilized constitutive overexpression
of Snail114,15,18. Triple Negative Breast Cancer cell lines
(classiﬁed as Mesenchymal-type) and breast cancer cell
lines that have undergone EMT express higher levels of
GM-CSF and activate macrophages to an M2-like phe-
notype, suggesting that GM-CSF is necessary to induce
M2-like polarization of macrophages16, and thus, that
GM-CSF is pro-tumorigenic. This is perhaps surprising
since GM-CSF has been shown to elicit powerful immune
responses, is often used as an adjuvant to cancer vac-
cines39 and overexpressing GM-CSF can inhibit tumor
growth and metastasis40. This is also in contradiction with
our ﬁndings since we showed in two mouse model of
breast cancer metastasis, that GM-CSF expression by
tumor cells is repressed by the presence of SNAIL1 and
in vivo GM-CSF treatment has an anti-metastatic effect.
Furthermore, GM-CSF receptor signaling has been shown
to ﬁne tune the molecular proﬁle of M1-like macro-
phages, although it does not seem to regulate monocyte
recruitment and differentiation26. These apparent con-
ﬂicting roles for GM-CSF can be due, at least in part, to
differences in GM-CSF dose, inﬂuence of other
Fig. 5 GM-CSF rescues the macrophage polarization in vitro. a In vitro polarization of BMDM by conditioned media from 4T1-shScr (shScr), 4T1-
shSnail1 (shSnail1) and 4T1-shSnail1 in the presence of anti GM-CSF antibody (shSnail1+ αGM-CSF) expressed as the CD206 Mean Fluorescence
Intensity (MFI) of TAM with representative image in b. Representative results from two biological replicates with technical triplicates. Average tumor
volume of mice orthotopically transplanted with 4T1-shScr (shScr) cells and 4T1-shScr cells with injections of GM-CSF (shScr+ GM-CSF) 12 days (c)
and 25 days (d) post orthotopic transplant. Data are presented as mean ± SD. *p < 0.05
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Fig. 6 Rescue of lung metastasis and macrophage polarization in vivo with the addition of GM-CSF. Average number of lung metastasis of
mice orthotopically transplanted with 4T1-shScr (shScr) cells and 4T1-shScr cells with injections of GM-CSF (shScr+ GM-CSF) 12 days (a) and 25 days
(b) post orthotopic transplant. Four to ﬁve mice per group. Quantiﬁcation of tumor inﬁltrated M1-like macrophages in tumors from 4T1-shScr (shScr)
transplants and 4T1-shScr with injections of GM-CSF (shScr+ GM-CSF) 12 days (c) and 25 days (d) post transplant. Four to ﬁve mice per group. e
Average number of lung metastasis of mice intravenously injected with 4T1-shScr (shScr) cells, 4T1-shSnail1 (shSnail1) and 4T1-shScr cells with
injections of GM-CSF (shScr+ GM-CSF) 7 days post IV injection. Data are presented as mean ± SD. *p < 0.05 and ns is not signiﬁcant (p > 0.05)
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stimulating factors or nature of the existing inﬂammatory
response41,42.
In this study, we showed that SNAIL1 regulates
expression of cytokines in primary breast tumor cells
including IL-1α, IL-6, TNFα, and GM-CSF. SNAIL1
represses the production of pro-inﬂammatory cytokines
IL-1α and TNFα and inhibits production of GM-CSF, a
known stimuli of M1-like macrophages leading to a
suppression of the pro-inﬂammatory response elicited by
the tumor cells. Different studies have shown that
SNAIL1 in tumor cells can regulate different sets of
cytokines and chemokines. SNAIL1 activates expression
of CCL2, CCL5, IL-6, TNFα, and IL-8 in head and neck
cancer cells and overexpression of SNAIL1 in 4T1 cells
increased inﬁltration of M2-like macrophages and pro-
moted metastasis in a breast cancer orthotopic model17.
We also observed regulation of CCL2, CCL5, IL-6, and
TNFα mRNA levels by SNAIL1 but this did not translate
to a signiﬁcant difference in secreted proteins with the
exception of IL-6 and TNFα.
Our data indicate that when SNAIL1 expression is
activated in tumor cells, they produce less pro-
inﬂammatory cytokines IL1α and TNFα and M1-like sti-
mulating GM-CSF. This leads to a reduction in the pro-
inﬂammatory tumor response, that appears to positively
inﬂuence metastasis.
B and T lymphocytes also exert pro-tumor activity
indirectly by regulating the activity of myeloid cells
including macrophages, monocytes and mast cells,
resulting in resistance to endocrine therapies and
increased metastasis43. We did not see any signiﬁcant
difference in the number of total T cells, T helper cells or
cytotoxic T cells or in their activation levels suggesting
that the action of SNAIL1 in tumor cells has little impact
upon recruitment of these immune populations. Our data,
however, does not exclude the possibility that regulatory
T cells or dendritic cells are affected as it has been
observed when overexpressing SNAIL1 in melanoma
cells18.
In conclusion, we show that the action of SNAIL1 in
breast tumor cells modulates the immune microenviron-
ment within breast tumors by regulating expression of
cytokines including GM-CSF. In breast cancer, SNAIL1
direct or indirect regulation of GM-CSF appears to have a




BALB/C and FVB mice were purchased from Charles
River. Conditional SNAIL1 knock out mice (SNAIL1 KO)
were generated by crossing Snail1ﬂ/ﬂ mice44 with MMTV-
Cre mice (Tg(MMTV-cre)4Mam). Inguinal mammary
glands number 4 from 4 to 5 week old females were
retrieved, Carmine Alum (Sigma-Aldrich) stained and the
ductal-invaded area was calculated using ImageJ software.
The mammary outgrowth was determined as the area of
epithelium growth (as demarcated) divided by the total
area of the mammary fat pad. Conditional mice were
crossed to MMTV-PyMT mice (SNAIL1 KO, PyMT) to
generate mammary tumors. The tumor burden was cal-
culated as the total of the tumor volumes using the
equation V= 0.52 × length × (width)2. Tumor grading was
made blindly as round or invasive as the examples shown
in the supplemental ﬁgures. For mammary orthotopic
transplants, 106 cells were injected in the right inguinal fat
pad number 4. For intravenous (IV) injections, 5 × 105
cells were injected in saline solution in the mouse tail
vein. No randomization was used as mice were injected
with either shScr or shSnail1 cells. Sample size calculation
for equal variance t-test showed the sample size needed
was seven per group to achieve the statistical power of 0.9.
All procedures involving animals and their care were
performed in accordance with the guidelines of the
American Association for Accreditation for Laboratory
Animal Care and the U.S. Public Health Service Policy on
Human Care and Use of Laboratory Animals. All animal
studies were also approved and supervised by the
Washington University Institutional Animal Care and Use
Committee in accordance with the Animal Welfare Act,
the Guide for the Care and Use of Laboratory Animals
and NIH guidelines (Protocol 20150145).
Cells, viral production, and transduction
4T1 cells were purchased from ATCC by our laboratory
in 2014. Cells were cloned and a high SNAIL1 expressing
clone was selected. The PMT cell line was derived from
an MMTV-PyMT mammary tumor, immortalized
through at least ten passages and FACS sorted for the
CD140a (PDGFR, eBioscience Clone APA5) negative
population. Viral production was carried out using
TransIT-LT1 (Mirus Bio) mediated transfection of
HEK293T cells. Virus was concentrated by ultra-
centrifugation, and added to the cells with Polybrene.
4T1 cells (ATCC) or PMT cells were transduced with
GIPZ-SCR or GIPZ-Snai1 (Thermo Scientiﬁc, 3 shRNA
tested, most efﬁcient knock down selected for subsequent
studies) for shRNA knock-down of SNAIL1. Stably
transduced cells were selected in puromycin for at least
5 days. Knock-down of SNAIL1 was conﬁrmed by Wes-
tern Blot. Cells were not passaged more than 15 times.
Cells were tested for Mycoplasma by PCR ampliﬁcation
using primers Myco+ (5′-GGG AGC AAA CAG GAT
TAG ATA CCC T-3′) and Myco− (5′-TGC ACC ATC
TGT CAC TCT GTT AAC CTC-3′) every 6 months and
treated for a minimum of 2 weeks with Plasmocin (Invi-
voGen) if the Mycoplasma PCR was positive, until the
PCR was negative.
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Western blotting
Cells were lysed in RIPA Buffer plus protease inhibitors
(Sigma-Aldrich). Protein concentration was measured
using the Bradford Reagent (Biorad). Lysates were sub-
jected to SDS-PAGE, transferred to PVDF membranes,
blocked in 5% milk, incubated with primary antibody
overnight, secondary antibody for 2 h and visualized using
the detection kits SuperSignal WestPico and/or Super-
Signal West Femto Chemiluminescent Substrates
(Thermo Fisher Scientiﬁc). Exposures were acquired
using a ChemiDoc Imager (BioRad). Antibodies used
include β-actin (A1978, Sigma Aldrich), Mouse SNAIL1
(L70G2, Cell Signaling), SLUG/SNAIL2 (C19G7, Cell
Signaling) and HRP anti-Mouse IgG (Cell Signaling).
Analysis of lung metastasis
Lungs and tumors were ﬁxed overnight in 10% Neutral
Buffered Formalin, washed in PBS, 30% ethanol, 50%
ethanol, and 70% ethanol then processed and embedded
in parafﬁn blocks. Tissue sections (5–6 μm) were stained
with H&E. Microscopically visible metastasis were coun-
ted by a blinded investigator from three sections taken 30
μm apart and reported as the average number of metas-
tases per lung lobe. Metastasis size was quantiﬁed by
ImageJ and expressed as number of pixels.
Flow cytometry analysis of tumor inﬁltrated immune cells
For ﬂow cytometry, all mice were perfused with Heparin
in PBS, mammary tumors were mechanically dissociated
with scissors and the tissue was digested in culture med-
ium (DMEM) with 2mg/ml Collagenase A (Roche) and 2
μg/ml DNAse (Sigma Aldrich) at 37 °C for 30min with
agitation. Digestion mixtures were quenched by adding
10% FBS and samples were ﬁltered through a 40 μm cell
strainer (Falcon). Cells were stained for 20–30min in the
dark on ice with the conjugated antibodies as follows
(eBioscience unless otherwise noted) following manu-
facturer’s recommended concentrations: Myeloid panel:
CD45 (30-F11), CD11b (M1/70), MHCII (M5/114.15.2),
Ly6C (HK1.4), Ly6G (1A8), F4/80 (BM8), CD206 (19.2,
BioRad) and T cell panel: CD45 (30-F11), CD3ε (145-
2C11), CD4 (L3T4), CD8α (53–6.7), CD62L (MEL-14),
and CD44 (IM7). Cells were then ﬁxed with BD Cytoﬁx
(BD Biosciences) and ﬂow cytometry was performed on a
BD LSRII ﬂow cytometer (BD Bioscience) and analyzed
using FlowJo software (TreeStar). Gating strategy was
performed as described in23 and the different populations
deﬁned as follow: G-MDSC (CD45+ CD11b+ Ly6G+
Ly6C+ MHCIIlow), Mo-MDSC (CD45+ CD11b+ Ly6G−
Ly6C+), Mature Granulocytes (Gran.) (CD45+ CD11b+
Ly6G+ Ly6C− MHCIIhigh), TAMs (CD45+ CD11b+
Ly6G− Ly6C− F4/80+ MHCII+), M1-like macrophages
(CD45+ CD11b+ Ly6G− Ly6C− F4/80+ MHCII+
CD206−), M2-like macrophages (CD45+ CD11b+ Ly6G−
Ly6C− F4/80+ MHCII+ CD206+), T cells (CD45+
CD3ε+), CD4+ T helper cells (CD45+ CD3ε+ CD4+),
CD8+ cytotoxic T cells (CD45+ CD3ε+ CD8+), activated
CD4+ T cells (CD45+ CD3ε+ CD4+ CD62L+ CD44high),
activated CD8+ T cells (CD45+ CD3ε+ CD8+ CD62L+
CD44high) as described in23. The populations are expressed
as a percent of parent. The parent populations are CD45+
CD11b+ Ly6G+ for mature granulocytes and G-MDSCs;
CD45+ CD11b+ Ly6G− for Mo-MDSC; CD45+ CD11b+
Ly6G− Ly6C− for TAM, total TAM for M1-like and M2-
like macrophages, live single cells for CD45+ cells, CD45+
cells for CD3 cells, and CD3 T cells for CD4 and CD8 cells.
BMDM polarization
Primary bone marrow was harvested from 6 to 8 weeks
old FVB mice. The femurs and tibias were dissected, the
epiphyses were removed and the bone marrow was ﬂu-
shed by centrifugation. Cells were cultured in Petri Dishes
in DMEM/F12 with 10% FBS and M-CSF (20 ng/ml,
Leinco Technologies) for 5 days. Cells were incubated for
3 days with ﬁltered conditioned media from 4T1 cells.
Brieﬂy, the 4T1 cells were cultured to near conﬂuency in
DMEM with 10% FBS then fresh media was conditioned
for 24 h by growing the 4T1 cells in DMEM without FBS.
BMDM polarization was analyzed by ﬂow cytometry
using MHCII and CD206 antibody as described above.
For the rescue experiments, anti Mouse-GM-CSF anti-
body (clone MP1-22E9, eBioscience, 1/500) was added to
the conditioned media before incubation with BMDM.
ELISA
Cells were seeded at 20% conﬂuency in DMEM with 5%
FBS and 2 ng/ml TGFβ and incubated for 3 days (each
condition was performed in biological triplicate). Filtered
supernatants (from equivalent number of cells) were
analyzed by Eve Technologies using the multiplex bead
platform Mouse Cytokine Array/Chemokine Array 31-
Plex.
Quantitative real-time RT-PCR (qRT-PCR)
Total RNA from 4T1-shScr and 4T1-shSnail1 cells was
isolated from cells using the RNeasy Mini Kit (Qiagen).
Complementary DNA (cDNA) was synthesized from 2 μg
of total RNA using the Superscript First Strand kit
(Invitrogen). mRNA levels were determined using semi
quantitative reverse transcriptase using Fast SYBR Green
(Applied Biosystems). Reactions were performed using
the comparative threshold cycle (Ct) method for relative
quantiﬁcation. The glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) was used as an endogenous control.
The data reported is the average of three technical repli-
cates of two independent biological replicates. Primer
sequences were designed using the PrimerBank web-
site45–47 and are listed in Supplemental Table S1.
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Total RNA was isolated from TAM (as deﬁned in Flow
Cytometry Analysis) sorted from 4T1-shScr and 4T1-
shSnail1 tumors 14 days post transplant. Cells were
processed and stained as described above and sorted on
the ARIAII system (BD). RNA was isolated using the E.N.
Z.A. Total RNA Kit (OMEGA) according to the manu-
facturer’s instructions. RNA was processed into cDNA
using qScript cDNA SuperMix (Quantabio). Target genes
were assessed using quantitative real-time PCR Taqman
primer probes sets (Applied Biosystems). Relative gene
expression was determined on an ABI7900HT quantita-
tive PCR machine (ABI Biosystems) using Taqman Gene
Expression Master Mix (Applied Biosystems). The
threshold cycle method was used to determine fold
change gene expression normalized to Gapdh and tbp.
GM-CSF dosing in vivo
GM-CSF (100 ng per mouse) or saline solution were
injected intraperitoneally every other day starting 7 days
before tumor cells injections and for the duration of the
experiment. After 7 days of GM-CSF injection, 106 4T1-
shScr or 4T1-shSnail1 cells were injected in the right
inguinal fat pad or 5.105 4T1-shScr or 4T1-shSnail1 were
injected via the tail vein and the GM-CSF or saline
solution injections were continued every other day for the
remaining of the experiment. Mice were sacriﬁced 12 or
25 days after mammary transplants or 7 days after tail vein
injection.
Statistical analysis
Statistical analysis was performed using Prism 4 soft-
ware (GraphPad Software). All data are presented as
mean ± standard deviation. The two-tailed Student t-test
was used. We considered p < 0.05 as signiﬁcant.
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